"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: A phase II study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Bruera, Gemma ^a   Santomaggio, Alessandra ^a   Cannita, Katia ^a   Baldi, Paola L ^a   Tudini, Marianna ^a   De Galitiis, Federica ^b   Mancini, Maria ^a   Marchetti, Paolo ^c   Antonucci, Adelmo ^d   Ficorella, Corrado ^a   Ricevuto, Enrico ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAN SALVATORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; BLEEDING; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GINGIVITIS; HEART MUSCLE ISCHEMIA; HEMATURIA; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOTENSION; LIVER METASTASIS; LIVER RESECTION; LOCAL METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RHINITIS; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; VOMITING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; METASTASIS; METHODOLOGY; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957916099     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-567     Document Type: Article

References (35)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GY, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000, 343:905-914. 10.1056/NEJM200009283431302, 11006366.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James R, Karasek P, Jandik P, Iveson F, Carmichael J, Alaki M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047. 10.1016/S0140-6736(00)02034-1, 10744089.
3. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18(1):136-47.
4. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2967.
5. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R, . Italian Trials in Medical Oncology (I.T.M.O.) Group Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004, 100(2):279-87. 10.1002/cncr.11910, 14716761, Italian Trials in Medical Oncology (I.T.M.O.) Group.
6. Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massida B, Cesaretti R, Tafuto S, Lorusso V, Leo S, Cannone M. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005, 104:282-289. 10.1002/cncr.21167, 15948167.
7. Grothey A, Goetz MP. Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. Clin Colorectal Cancer 2004, 4(Suppl 1):S37-42. 10.3816/CCC.2004.s.006, 15212704.
8. Kabbinavar FF, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21(1):60-65. 10.1200/JCO.2003.10.066, 12506171.
9. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23(16):3706-3712. 10.1200/JCO.2005.00.232, 15867200.
10. Hurwitz HI, Fehrenbacher L, Hainsworth J, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar FF. Bevacizumab in combination with fluorouracil and leucoverin: an alternative regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005, 23:3502-3508. 10.1200/JCO.2005.10.017, 15908660.
11. Hurwitz HI, Fehrenbacher L, Novotny WF, Cartwright T, Hainsworth J, Meropol NJ, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross M, Kabbinavar FF. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-234. 10.1056/NEJMoa032691, 15175435.
12. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-45. 10.1056/NEJMoa033025, 15269313.
13. Hochster HS, Hart LL, Ramanathan RK, Barrett HC, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, abubakr Y, Saif MW, Schwartzeberg L. Safety and efficacy of Oxaliplatin-Fluoropyrimidine regimens with or without Bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Results of the TREE study. J Clin Oncol 2008, 26:3523-3529. 10.1200/JCO.2007.15.4138, 18640933.
14. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, sirzen F, Cassidy J. Bevacizumab in combination with Oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019. 10.1200/JCO.2007.14.9930, 18421054.
15. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T. Bevacizumab, Capecitabine, and Oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008, 26:1830-1835. 10.1200/JCO.2007.13.7679, 18398148.
16. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Di Bartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D, . First BEAT investigators Safety and efficacy of first-line Bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20(11):1842-7. 10.1093/annonc/mdp233, 19406901, First BEAT investigators.
17. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25:1670-1676. 10.1200/JCO.2006.09.0928, 17470860.
18. Souglakos J, Andrulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kalolyris S, Tsousis S, Kouroussis CH, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V. FOLFOXIRI (folin acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folin acid, 5-fluorouracil and irinotecan) as first-line treatment in metestatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). British Journal of Cancer 2006, 94:798-805. 10.1038/sj.bjc.6603011, 2361370, 16508637.
19. Ficorella C, Ricevuto E, Morelli MF, Morese R, Cannita K, Cianci G, Di Rocco ZC, De Galitiis F, De Tursi M, Tinari N, Iacobelli S, Marchetti P. Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. Oncol Rep 2006, 15(5):1345-1350.
20. Garufi C, Lévi F, Aschelter AM, Pace R, Giunta S, Nisticò C, Gallà DA, Silecchia GF, Franchi F, Narduzzi C, Terzoli E. A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and l-folinic acid in patients with metastatic colorectal cancer. Eur J Cancer 1997, 33:1566-71. 10.1016/S0959-8049(97)00133-0, 9389916.
21. Cure H, Chevalier V, Pezet D, Bousquet J, Focan C, Levi F, Garufi C, Chipponi J, Chollet P. Phase II trial of chronomodulated infusion of 5-fluorouracil and l-folinic acid in metastatic colorectal cancer. Anticancer Res 2000, 20:4649-4654.
22. Morelli MF, Santomaggio A, Ricevuto E, Cannita K, De Galitiis F, Tudini M, Bruera G, Mancini M, Pelliccione M, Calista F, Guglielmi F, Martella F, Lanfiuti P, Porzio G, Russo A, Gebbia N, Iacobelli S, Marchetti P, Ficorella C, . CINBO (Consorzio Interuniversitario Nazionale per la Bio-Oncologia) Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in Advanced Colorectal Cancer: a dose-finding and phase II study. Oncol Rep 2010, 23(6):1635-40. CINBO (Consorzio Interuniversitario Nazionale per la Bio-Oncologia).
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
24. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J am Stat Assoc 1958, 53:457-481.
25. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10. 10.1016/0197-2456(89)90015-9, 2702835.
26. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelereted titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997, 89(15):1138-47. 10.1093/jnci/89.15.1138, 9262252.
27. Masi G, Salvatore L, Fornaro L, Vasile E, Baldi GG, Stasi I, Ciarlo A, Tuzi A, Andreuccetti M, Falcone A. Bevacizumab (BV) in combination with FOLFOXIRI (Irinotecan, Oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): update results of a phase II G.O.N.O. trial. EJC Supplements 2009, 17(2). (suppl; poster 6081).
28. Ficorella C, Morelli MF, Ricevuto E, Cannita K, Porzio G, Baldi PL, Cianci G, Di Rocco ZC, Natoli C, Tinari N, De Galitiis F, Calista F, Marchetti P. Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. Br J Cancer 2004, 91:618-20. 2364792, 15292944.
29. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 351:1408-17.
30. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, Leucoverin, and Oxaliplatin with or without Cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671. 10.1200/JCO.2008.20.8397, 19114683.
31. Douillard J, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel ME, Humblet Y, Cunningham D, Wolf M, Gansert JL. Randomized phase 3 study of Panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. EJC Supplements 2009, 17:3. (Suppl; abstact 10LBA).
32. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of Bevacizumab. J Natl Cancer Inst 2005, 97(13):981-9. 10.1093/jnci/dji174, 15998951.
33. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with Cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol 2009,
34. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000, 356:373-8. 10.1016/S0140-6736(00)02528-9, 10972369.
35. Falcone A, Loupakis F, Cupini S, Cortesi E, Buonadonna A, Tomasello G, Banzi M, Ronzoni M, Zaniboni A, Masi G. FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO). J Clin Oncol 2010, 28:15s. (suppl; abstr 3543).